✨ Introduction
Some By Mi AHA BHA PHA 14 Days Super Miracle Spot All Kill Cream 30ml is a fast-acting Korean spot treatment designed to target active acne, clogged pores, and post-inflammatory marks. Formulated with 750,000 ppm Truecica™, exfoliating acids, and calming botanicals, it helps reduce redness, flatten pimples, and fade dark spots in just 14 days. Its lightweight gel texture absorbs quickly without residue, making it ideal for use under makeup or overnight. Perfect for Bangladesh’s humid, acne-triggering climate, this cream delivers clarity, calm, and confidence.
🧴 How to Use
After cleansing and toning, apply a small amount directly onto troubled areas.
Use a clean fingertip or cotton swab for precise application.
Gently pat until absorbed.
Use morning and night for best results.
Follow with sunscreen during the day.
🌿 Hero Ingredients & Benefits
- Truecica™ (750,000 ppm): Combines Centella Asiatica, Tea Tree, Mugwort, and Titrated Extracts to soothe and protect acne-prone skin.
- AHA, BHA, PHA: Exfoliate dead skin cells, unclog pores, and smooth texture.
- Niacinamide: Brightens post-acne marks and improves skin tone.
- Calamine: Soothes irritation and reduces redness.
- Madecassoside: Strengthens the skin barrier and supports healing.
🧪 Full Ingredients List
Truecica™, AHA, BHA, PHA, Niacinamide, Calamine, Madecassoside, Tea Tree Leaf Extract, Centella Asiatica Extract, Glycerin, Panthenol, Butylene Glycol, 1,2-Hexanediol, Carbomer, Arginine, Ethylhexylglycerin, Disodium EDTA.
⚠️ Do & Don’t
Do:
- Use consistently for faster acne recovery.
- Apply extra product to inflamed or pigmented areas.
- Store in a cool, dry place away from sunlight.
Don’t: - Use on broken or severely irritated skin.
- Mix with strong actives (retinol, vitamin C) without guidance.
- Skip patch testing if you have highly reactive skin.
👤 Suitable Skin Types
✅ Acne-prone skin
✅ Oily or congested skin
✅ Sensitive skin
✅ Redness-prone or inflamed skin
❌ Not recommended for fungal acne-prone skin without patch testing
There are no reviews yet.